Diffusion tensor imaging in unclear intramedullary tumor-suspected lesions allows separating tumors from inflammation

Marc Hohenhaus, Yorn Merz, Jan-Helge Klingler, Christoph Scholz, Ulrich Hubbe, Jürgen Beck, Katharina Wolf, Karl Egger, Marco Reisert and Nico Kremers

© The Author(s) 2021

INTRODUCTION

Spinal cord tumors (SCT) are rare and surgical intervention is usually required [1, 2]. The neurological status and the histological diagnosis are the most important factors for long-term outcome [2–4]. Complete surgical resection is the primary goal for spinal ependymoma, hemangioblastoma and other non-infiltrating tumors. For infiltrating neoplastic entities, like astrocytic tumors or lymphomas, cautious procedures with biopsy for histological classification and following radiotherapy are primarily recommended. A non-surgical treatment is usually required [1, 2]. The neurological status and the histological diagnosis are the most important factors for long-term outcome [2, 7–9]. There are several newer MRI techniques, like MR spectroscopy, Phase-contrast imaging or Diffusion-weighted imaging, but which were mainly applied in studies. They have not entered clinical routine yet, because the precise diagnostic value is often still heterogeneous due to the rather small case series. Some spinal cord lesions present typical signal clusters within the conventional MRI sequences, like hemangioblastomas with usually strong nodular CE, vascularization, associated cysts and surrounding edema, or cavernomas with CE on T1-weighted images and usually blood degradation products within the spinal mass [7]. The characterization of other entities, especially the differentiation of astrocytic tumors and ependymomas, remains still challenging [7, 10, 11]. Diffusion tensor imaging (DTI), a special MRI technique with depiction of tissue diffusion alterations and perceptibility and anatomic resolution [5, 6]. Conventional acquired T2- and T1-weighted sequences without and with contrast enhancement (CE) are state of the art [2, 7–9].
strengths, was reported to enhance the diagnosis of entity and characteristics of SCT within some case series [12–16], but not yet in larger clinical trials. This effect seems to be based on the different structure of the tumor mass itself as well as the constitution of the surrounding spinal cord tissue [16].

Because of the high relevance for further treatment planning, it is crucial to improve the presurgical imaging diagnostics. We expected to gain an imaging-based differentiation of non-infiltrating ependymomas from other SCT and inflammatory lesions by a specific quantitative DTI parameter configuration.

METHODS
The aim of this prospective, diagnostic study was to investigate specific quantitative signal patterns to classify unclear intramedullary tumor-suspected lesions based on DTI.

Study population
Patient data were sampled within a prospective, single-center, single-arm cohort study. The study was approved by the local ethics committee (reference 145/14) and reported to the national clinical trial registry (DRKS00008994). We prospectively included patients who presented with an unclear, intramedullary, tumor-suspected lesion through the outpatient clinic or the Emergency Center of the Department of Neurosurgery and Neuroradiology of the University Medical Center Freiburg between 2014 and 2019. All patients gave their written consent. In case of age <18 years, the consent was given by a parent or legal guardian. Patients with radiological clearly definable diagnosis on conventional MRI, like hemangioblastoma, cavernoma or lipoma, were excluded. Additional exclusion criteria were the common MRI contraindications.

Patient data
Patients’ baseline characteristics and clinical status by modified McCormick Score (mMCS) were documented [17]. There was no defined follow-up procedure for the included patients due to the primary diagnostic imaging setting of the study.

Evaluation of conventional MRI
According to the usual radiological work-up, conventional T1-weighted sequences in sagittal and transverse plane without and with contrast agent and T2-weighted sequences in sagittal und transverse plane were analyzed in every patient concerning the following common imaging features: none, slight (thickened spinal cord with remaining perimedullary cerebrospinal fluid space) or severe (thickened spinal cord with complete occupation of the spinal canal) space occupation; central or asymmetric intramedullary position; presence of one or multiple associated tumor cysts or intralesional hemorrhages; no, mild (less than two vertebral bodies), moderate (two to five vertebral bodies) or extensive (more than five vertebral bodies) perilesional edema; presence of no, focal nodular, annular or diffuse CE, as well as the occurrence of a syrinx. The evaluation was done independently by one experienced radiologist (NK) and one instructed post-graduate student (YM). Inter-observer variability was calculated and for further evaluation both had to reach consensus.

Study imaging protocol
All patients received an additional high-resolution, three-dimensional T2-weighted SPACE sequence as anatomical reference and a study-specific DTI sequence using a 3.0T scanner (SIEMENS®, Erlangen, Germany). DTI was performed using the RESOLVE sequence (Readout Segmentation Of Long Variable Echo-trains, SIEMENS®) with the following imaging parameters: axial acquisition, TR 7000 ms, TE 77 ms, Matrix 110 × 110, slice thickness 3 mm.

Table 1. Baseline characteristics of all patients and separated for the diagnostic groups.

|                          | All patients | Ependymoma | Other SCT | Inflammation | Indeterminate |
|--------------------------|--------------|------------|-----------|--------------|---------------|
| Number of patients       | 40           | 10         | 8         | 8            | 14            |
| Male: Female             | 18:22        | 6:4        | 2:6       | 6:2          | 4:10          |
| Age, years, mean (SD)a   | 45.4 (18.3)  | 52.6 (18.9)| 43.5 (25.0)| 38.3 (11.6)  | 45.5 (16.6)   |
| mMCSb                    |              |            |           |              |               |
| 0                        | 7            | 0          | 1         | 0            | 6             |
| 1–2                      | 18           | 7          | 3         | 3            | 5             |
| 3–5                      | 14           | 3          | 4         | 5            | 2             |

SCT spinal cord tumors, mMCS modified McCormick score.
aThere was no significant difference for age between the four diagnosis groups (p = 0.396).
bFor the 2-year-old child the mMCS could not be determined.
Table 2. Conventional MRI characteristics of all 40 patients.

| No. | Age | Localization | Conventional MRI characteristics | Treatment | Diagnosis            |
|-----|-----|--------------|-----------------------------------|-----------|----------------------|
|     |     |              | Space occupation | Intramedullary position | Cysts | Hemorrhage | Edema | Contrast enhancement | Syrinx |                       |
| 1   | 62  | T6/7         | Slightly            | Central                  | Multiple | Yes  | No  | Diffuse | Yes  | Resection | Ependymoma       |
| 2   | 75  | T10          | Slightly            | Central                  | One     | No   | No  | Extensive | Nodular | Yes        | Resection | Ependymoma       |
| 3   | 80  | T2/3         | Severely            | Central                  | No      | No   | Yes | Extensive | Diffuse | No         | Resection | Ependymoma       |
| 4   | 47  | C1/2         | Severely            | Central                  | Multiple | Yes  | No  | Extensive | Annular | Yes        | Resection | Ependymoma       |
| 5   | 67  | C3/4         | Slightly            | Central                  | Multiple | Yes  | No  | Moderate | Nodular | No         | Resection | Ependymoma       |
| 6   | 57  | C5           | Slightly            | Central                  | Multiple | Yes  | No  | Moderate | Nodular | No         | Resection | Ependymoma       |
| 7   | 43  | C5-T2        | Severely            | Central                  | Multiple | Yes  | No  | Moderate | Diffuse | No         | Resection | Ependymoma       |
| 8   | 43  | C7/T1        | Slightly            | Central                  | No      | No   | No  | Mild     | No     | No         | Resection | Ependymoma       |
| 9   | 30  | C0-3         | Severely            | Central                  | No      | No   | No  | No       | Nodular | No         | Resection | Ependymoma       |
| 10  | 22  | C0-2         | Severely            | Central                  | Multiple | No   | No  | Moderate | Diffuse | No         | Resection | Ependymoma       |
| 11  | 46  | T3-7         | Severely            | Central                  | Multiple | Yes  | No  | Mild     | Diffuse | Yes        | Biopsy    | Anaplastic astrocytoma |
| 12  | 64  | C3/4         | Slightly            | Central                  | No      | No   | No  | Mild     | Diffuse | No         | Resection | Anaplastic astrocytoma |
| 13  | 65  | T5/6         | Severely            | Central                  | No      | Yes  | No  | Extensive | Diffuse | Yes        | Resection | Hemangiopericytoma |
| 14  | 11  | C3-7         | Severely            | Central                  | Multiple | No   | No  | Mild     | Nodular | No         | Resection | Pilocytic astrocytoma |
| 15  | 11  | C2/3         | Severely            | Central                  | One     | No   | No  | Mild     | Annular | No         | Resection | Pilocytic astrocytoma |
| 16  | 38  | C1-4         | Slightly            | Central                  | Multiple | Yes  | No  | Mild     | Diffuse | No         | Biopsy    | Gliotic tumorous process |
| 17  | 34  | T12/L1       | Slightly            | Asymmetric               | No      | No   | No  | Mild     | No     | No         | Biopsy    | Low-grade glioma |
| 18  | 79  | T7/8         | Slightly            | Central                  | No      | No   | No  | Moderate | Diffuse | No         | Clinical Diagnostics | B-cell lymphoma |
| 19  | 33  | T3-5         | Slightly            | Asymmetric               | No      | No   | No  | Moderate | Nodular | No         | Biopsy    | Acute inflammation |
| 20  | 47  | T4/5         | Slightly            | Central                  | No      | No   | No  | Mild     | Annular | No         | Clinical Diagnostics | Clinically isolated syndrome |
| 21  | 23  | T5-8         | Slightly            | Central                  | No      | No   | No  | Mild     | Annular | No         | Clinical Diagnostics | Clinically isolated syndrome |
| 22  | 35  | T7/8         | Slightly            | Asymmetric               | No      | No   | No  | Diffuse | No     | No         | Biopsy    | Clinically isolated syndrome |
| 23  | 32  | T9           | Slightly            | Asymmetric               | No      | No   | No  | Mild     | Diffuse | No         | Clinical Diagnostics | Clinically isolated syndrome |
| 24  | 58  | C3           | Slightly            | Asymmetric               | No      | No   | No  | Diffuse | No     | No         | Clinical Diagnostics | Clinically isolated syndrome |
| 25  | 30  | C4           | No                 | Asymmetric               | No      | No   | No  | No      | No     | No         | Clinical Diagnostics | Clinically isolated syndrome |
| 26  | 48  | C1-5         | Slightly            | Asymmetric               | No      | No   | No  | Extensive | Diffuse | No         | Clinical Diagnostics | Postinfectious myelitis |
| 27  | 32  | C1/2         | Slightly            | Central                  | No      | No   | No  | Yes      | Moderate | No         | decompression | Indeterminate |
| 28  | 52  | C3/4         | Slightly            | Central                  | Multiple | Yes  | No  | Nodular | No     | No         | Conservative | Indeterminate |
| 29  | 2   | C2-7         | Severely            | Asymmetric               | No      | No   | No  | Moderate | No     | No         | Conservative | Indeterminate |
| 30  | 58  | C2/3         | Slightly            | Asymmetric               | No      | No   | No  | Diffuse | No     | No         | Conservative | Indeterminate |
| 31  | 35  | C3/4         | Slightly            | Central                  | Multiple | Yes  | No  | No      | No     | No         | Conservative | Indeterminate |
Evaluation of DTI

The image post-processing was done through the specialized in-house software pipeline NORA (www.nora-imaging.org) and for tensor calculation, the following open source toolbox was used: https://www.uniklinik-freiburg.de/mr-en/research-groups/diffperf/fibertools.html. For calculation of the DTI parameters we defined seven regions of interest (ROI) for every tumor-suspected lesion: cranial normal spinal cord, cranial edema, cranial lesion margin, central lesion area, caudal lesion margin, caudal edema, and caudal normal spinal cord. For further analysis we calculated the mean of the cranial and caudal value, if both anatomical locations were available for ROI setting. If there was only a cranial or caudal ROI definable, the single value was used. Principle of ROI setting is depicted in Fig. 1. Spherical ROI were applied with a radius of two voxels placed on the fractional anisotropy (FA) and apparent diffusion coefficient (ADC) maps with corresponding 3D T2-weighted images as anatomical correlation. Within every ROI, the average FA and ADC values were calculated. All ADC values are given in $10^{-3}$ mm$^2$/s.

Statistics

Data processing and statistical analysis were performed using IBM SPSS® (Version 25). The inter-observer reliability for the radiographic conventional MRI characteristics was determined by Kappa statistics [21]. Normal distribution was assessed by Shapiro–Wilk-test. t-Test for unpaired samples for normally distributed values and Mann–Whitney U test for non-normally distributed values were used to compare the different entity groups. Levene's test was used to assess the equality of variances. $p$ value $<0.05$ was considered statistically significant.

RESULTS

Baseline characteristics study population

We prospectively included 40 patients with a mean age of 45.4 (SD 18.3) years. Gender distribution showed 18 male (45.0%) and 22 female (55.0%) patients. Eighteen patients (45.0%) reported pain and/or showed mild neurological deficits like paresthesia or slight gait disturbance (mMCS 1 or 2), whereas 14 patients (35.0%) were severely neurologically deteriorated (mMCS 3–5). Seven patients (17.5%) with a spinal cord lesion showed only non-specific symptoms, like neck pain or dizziness, leading to primary MRI diagnostics. They are stated as mMCS 0. For the 2-year-old child, the mMCS could not be determined.

After inclusion into the study and DTI measurement, 26 of all 40 patients received a definite diagnosis through their clinical diagnostic work-up or following surgical treatment. Eighteen patients (45%) had a histological proven SCT, whereof ten patients (25%) showed an ependymoma and eight patients (20%) another SCT. In eight patients (20%), an inflammatory process could be detected. Therefore, the left 14 patients (35%) remained without an indeterminate diagnosis without a specific treatment, thus receiving imaging and clinical follow-up examinations. The mean follow-up time for patients with an indeterminate lesion was 31.4 (SD 28.0) months, whereas the diagnosis remained still unclear for this whole time period. The clinical course and follow-up time period of every patient with an indeterminate lesion was predefined seven regions of interest (ROI) for every ROI, the average FA and ADC values were calculated. All ADC values are given in $10^{-3}$ mm$^2$/s.

**Table 2. Continued**

| No. | Age | Localization | Conventional MRI characteristics | Space occupation | Intramedullary position | Cysts | Hemorrhage | Edema | Contrast enhancement | Nodular | Syrinx | Treatment | Diagnosis |
|-----|-----|--------------|---------------------------------|------------------|------------------------|-------|------------|-------|---------------------|--------|--------|-----------|-----------|
| 32  | 43  | C4           | Slightly                        | Central          | Central                | No    | No         | No    | No                  | Nodular | No     | Conservative| Indeterminate|
| 33  | 55  | C4           | Slightly                        | Central          | Central                | No    | No         | No    | No                  | Nodular | No     | Conservative| Indeterminate|
| 34  | 41  | C4/5         | Slightly                        | Central          | Central                | No    | No         | One   | No                  | Nodular | No     | Conservative| Indeterminate|
| 35  | 56  | C5/6         | Slightly                        | Central          | Central                | No    | No         | No    | No                  | Nodular | No     | Conservative| Indeterminate|
| 36  | 74  | C7/T4        | Slightly                        | Central          | Central                | No    | No         | No    | No                  | Nodular | No     | Conservative| Indeterminate|
| 37  | 48  | C7/T1        | Severely                        | Central          | Central                | No    | No         | No    | No                  | Nodular | No     | Conservative| Indeterminate|
| 38  | 56  | T2           | Severely                        | Central          | Central                | No    | No         | No    | Nodular             | No      | No     | Conservative| Indeterminate|
| 39  | 45  | T3/T4        | Severely                        | Central          | Central                | No    | No         | No    | No                  | Nodular | No     | Conservative| Indeterminate|
| 40  | 40  | T3/T4        | Severely                        | Central          | Central                | No    | No         | No    | Nodular             | No      | No     | Conservative| Indeterminate|

**Table 2. Continued**

This patient received a resection of the cerebral pathology found in the staging of the complete neuroaxis and additional cerebrospinal fluid sampling, resulting in the diagnosis of an intramedullary metastasis of the cerebral anaplastic astrocytoma.
Fig. 2 Boxplots for the FA (above) and ADC (below) metrics of all three definite diagnosis groups. SCT = spinal cord tumors. All ADC values are given in $10^{-3} \text{mm}^2/\text{s}$. *p-values: Group comparison using Mann–Whitney U test because of non-normally distributed FA values within the central tumor area for ependymomas and within the edema for other SCTs as well as the ADC values within the central tumor area for other SCTs. For all other group comparisons t-test for unpaired samples was applied.

**Conventional MRI**
The predominant location of the intramedullary lesions was the cervical spine ($n = 25$, 62.5%), whereof two lesions expanded to the craniocervical junction and four to the thoracic spine. The other lesions were located at the thoracic spine ($n = 15$, 37.5%) with one tumor expanding to the upper lumbar spine. The consensus MRI lesion characteristics of both raters for every patient are shown in Table 2. The absolute agreement of both raters for all seven evaluated lesion characteristics in all 40 patients was 83.2% (233 of in total 280 ratings). By consensus reading, the final decision was adjusted predominantly toward the experienced radiologist in 35 of the 47 disagreed cases (74.5%). The absolute agreement separated for each lesion characteristic and the associated Kappa values were added as Supplementary 2. The interobserver reliability was “moderate” to “almost perfect” with the following Kappa ($\kappa$) values: Space occupation $\kappa = 0.641$ (SD 0.117, $p < 0.001$), intramedullary position $\kappa = 0.827$ (SD 0.095, $p < 0.001$), cysts $\kappa = 0.744$ (SD 0.091, $p < 0.001$), hemorrhage $\kappa = 0.630$ (SD 0.148, $p < 0.001$), edema $\kappa = 0.560$ (SD 0.098, $p < 0.001$), CE $\kappa = 0.579$ (SD 0.101, $p < 0.001$), syrinx $\kappa = 0.725$ (SD 0.150, $p < 0.001$) [21].

**Diffusion tensor imaging**
Because of the heterogeneous lesion location and expansion, the ROI setting had to be adapted individually, like mentioned within the methods section. In all patients we could define a ROI at the central lesion area and at the lesion margin. But not every patient showed a perilesional edema or normal spinal cord areas within the field of view. The number of applicable ROI for every patient group is attached as Supplementary 3.

We separated our DTI parameter evaluation for patients with a distinct ($n = 26$) and patients with an indeterminate diagnosis ($n = 14$).

For the central lesion area, SCT showed significantly lower mean FA values compared to the inflammation group (0.249 (SD 0.106) vs. 0.457 (SD 0.081), $p < 0.001$). This significant difference remained at the lesion margin (0.333 (SD 0.129) vs. 0.526 (SD 0.048), $p < 0.001$). The mean ADC values were significantly higher in SCT at the lesion margin (1.487 (SD 0.273) vs. 1.027 (SD 0.241), $p = 0.001$), without reaching statistical significance at the central lesion area ($p = 0.129$). The perilesional edema and the normal spinal cord areas showed no significant differences for both DTI parameters.

The comparison of the two SCT subgroups revealed no significant differences for all evaluated areas (Fig. 2). Ependymomas showed the lowest mean FA at the central lesion area (0.240 (SD 0.099)) and the lesion margin (0.322 (SD 0.147)) and the highest mean ADC values for both areas (1.300 (SD 0.502) and 1.528 (SD 0.265)) without reaching statistical significance compared to the other SCT ($p = 0.237–0.694$, Table 3 and Fig. 2). For the comparison of both SCT subgroups with the inflammations, the differences remained similar to all SCT together (Fig. 2) for the central and margin lesion areas. For the perilesional edema, a statistically significant difference was only detected for the ADC between ependymoma and the inflammation group (1.600 (SD 0.304) vs. 1.154 (SD 0.282), $p = 0.040$, Fig. 2) with a marginally non-significant trend for the FA (0.355 (SD 0.134) vs. 0.479 (SD 0.069), $p = 0.081$). The normal spinal cord areas showed no significant differences between all groups as expected (Fig. 2).

Some data were not normally distributed, therefore the following subgroups were compared by Mann–Whitney U test: FA at the central tumor area for ependymomas and at the edema for other SCT, as well as ADC values at the central tumor area for other SCT and patients with indeterminate diagnosis. The average values were given as mean values for the sake of clarity.

Figure 3 depicts the scatterplots of all 40 evaluated patients for the FA values within the central lesion area and the lesion margin. There was a noticeable clustering from lower FA values in ependymomas to increasing values in other SCT and inflammations (from left to right). The depiction of the indeterminate diagnosis at the right side of the scatterplot (light gray) shows a wide range of FA values from 0.101 to 0.525 for the central lesion area and 0.172 to 0.635 for the lesion margin.

**DISCUSSION**
Aim of this study was to detect a specific DTI parameter configuration to separate spinal ependymomas from other SCT and inflammatory diseases. We could demonstrate significantly lower FA and increased ADC values for spinal cord neoplasms compared to inflammatory lesions. Based on our current DTI measurements, a reliable separation of ependymomas from other SCT was not feasible.

This is in line with one of our previous publications showing successful separation of patients with inflammatory lesions due to DTI-based subjective streamline analysis [22]. Inflammatory pathologies presented consistently with normal appearing
Fractional anisotropy (FA) Apparent diffusion coefficient (ADC)

| Condition                  | Ependymoma | Other SCT | Inflammation | Indeterminate |
|----------------------------|------------|-----------|--------------|---------------|
| Central lesion area (mm²)  | 0.240 (0.099) | 0.260 (0.120) | 0.457 (0.081) | 0.295 (0.124) |
| Mean (SD)                  | 0.240 (0.099) | 0.260 (0.120) | 0.457 (0.081) | 0.295 (0.124) |
| Lesion margin (mm²)        | 0.322 (0.147) | 0.347 (0.107) | 0.526 (0.046) | 0.446 (0.144) |
| Mean (SD)                  | 0.322 (0.147) | 0.347 (0.107) | 0.526 (0.046) | 0.446 (0.144) |
| Edema (mm)                 | 0.335 (0.134) | 0.423 (0.125) | 0.479 (0.069) | 0.391 (0.161) |
| Mean (SD)                  | 0.335 (0.134) | 0.423 (0.125) | 0.479 (0.069) | 0.391 (0.161) |
| Healthy spinal cord (mm)   | 0.567 (0.032) | 0.519 (0.038) | 0.599 (0.085) | 0.515 (0.132) |
| Mean (SD)                  | 0.567 (0.032) | 0.519 (0.038) | 0.599 (0.085) | 0.515 (0.132) |

All ADC values are given in 10⁻³ mm²/s.

Image and text: Fractional anisotropy (FA) and apparent diffusion coefficient (ADC) values for different spinal cord lesions. The FA values increase from left (ependymomas) to right (inflammatory lesions) and are highest in ependymomas. ADC values show higher values in normal spinal cord segments compared to lesions. The decrease in diffusion strength compared to normal spinal cord segments is used as a diagnostic tool.

Pathological diffusion alterations, depicted through abnormal DTI values, are known to reflect different cellular structures within neoplastic as well as the surrounding tissue of the spinal cord. There are some smaller case series showing decreased FA and elevated ADC values in intramedullary astrocytomas compared to healthy spinal cord [13, 23, 24]. This reflects a disturbed structure of the normally high anisotropic white matter of the spinal cord with its parallel orientation of nerve fibers.

The differentiation of the intramedullary tumor entities itself is still challenging. Maj et al. reported a DTI-based differentiation of infiltrating and non-infiltrating SCT in 18 patients [16]. Significant higher FA values were detected for non-infiltrating ependymomas (n = 12) compared to infiltrating astrocytomas (n = 6) - at the peritumoral margins (0.399 (SD 0.08) vs. 0.304 (SD 0.1), p = 0.007) and peritumoral edema (0.439 (SD 0.11) vs. 0.350 (SD 0.1), p = 0.029). There was no significant FA difference within the tumor mass itself (0.205 (SD 0.1) vs. 0.228 (SD 0.1), p = 0.470). The ADC values were significantly higher within the tumor mass for non-infiltrative tumors (1.59 (SD 0.55) vs. 1.12 (SD 0.2), p = 0.016) but without a significant difference for the peritumoral margin or edema. They postulated higher tumor cellularity in the peritumoral zone of infiltrating tumors to be responsible for the FA decrease.

Table 3. DTI measurements at the different evaluated anatomical areas for all four diagnostic groups.

| Condition                  | Ependymoma | Other SCT | Inflammation | Indeterminate |
|----------------------------|------------|-----------|--------------|---------------|
| Central lesion area (n)    | 10         | 8         | 8            | 14            |
| Mean (SD)                  | 0.260 (0.120) | 0.260 (0.120) | 0.260 (0.120) | 0.260 (0.120) |
| Lesion margin (n)          | 10         | 8         | 8            | 14            |
| Mean (SD)                  | 0.347 (0.107) | 0.347 (0.107) | 0.347 (0.107) | 0.347 (0.107) |
| Edema (n)                  | 7          | 4         | 6            | 7             |
| Mean (SD)                  | 0.423 (0.125) | 0.423 (0.125) | 0.423 (0.125) | 0.423 (0.125) |
| Healthy spinal cord (n)    | 5          | 4         | 4            | 7             |
| Mean (SD)                  | 0.567 (0.032) | 0.519 (0.038) | 0.599 (0.085) | 0.515 (0.132) |

All ADC values are given in 10⁻³ mm²/s.

SPRINGER NATURE

Spinal Cord (2022) 60:655 – 663
cohort were comparable with values reported in literature and therefore reliable (FA: mean 0.545 (SD 0.106) and ADC: mean 1.101 (SD 0.360)) [16, 27].

Overall, there are some former reports of a reproducible differentiation of neoplastic lesions from healthy spinal cord and inflammatory lesions, which could be confirmed throughout our results. We might postulate, that a primarily unclear tumor-suspected lesion with a FA > 0.4 or ADC ≈ 1.0 is suggestive for an inflammatory disease without indication for surgery or biopsy. Grounding on the pathophysiology, the inflammatory lesions might have a less strong disarranged diffusion compared to the normal spinal cord because of the potential integrity of the tissue structure. This has a relevant clinical impact, because of the non-invasive differentiation of neoplastic and non-neoplastic lesions with their primary conservative treatment. There are still several reports of spinal cord biopsies in inflammatory lesions, like even in our cohort (No. 19 and 22) [28, 29]. This is a risk for neurological deterioration and has to be avoided.

There are different areas of interest for the evaluation of DTI metrics in a tumor-suspected lesion. We detected alterations at all anatomical sites: the central lesion area as well as at the lesion margin and the associated edema. Maj et al. showed significant differences at the peritumoral margin and edema for the FA and at the tumor mass for the ADC [16]. For the differentiation of neoplastic and inflammatory lesions, the lesion margin showed consistently significant differences for both parameters, FA and ADC, whereas at the central lesion area only revealed significances for the FA. Therefore, the margin of the suspected lesion seems to be the most relevant area for evaluation.

Fourteen of all included patients remained without definite diagnosis ("indeterminate"). Due to no (six patients) or minor neurological deterioration (three patients with mMCS 1 and two patients with mMCS 2) or declining surgical treatment, these patients underwent follow-up examinations. The DTI metrics for this patient group showed values ranging throughout the whole spectrum as depicted in Fig. 3 in light gray (FA values 0.101–0.525 for the central lesion area and 0.172–0.635 for the lesion margin, mean (SD) shown in Table 3). We suspect, that correspondingly all possible entities are reflected within this group. Unfortunately, we received no definite diagnosis for precise evaluation.

A major limitation, also within our work, is the low incidence of SCT resulting in a small sample size for mono-centric studies. This restriction can only be solved by larger multi-center trials or (inter-)national register studies. Another limitation seems to be the heterogeneous dimension of the tumor-suspected lesions. Tumors with a large space occupation or enormous edema might show
more heterogeneous signal clusters than smaller lesions. Side effects like intratumoral hemorrhages, a large syrinx or even signal artifacts (like patient No. 8) may affect the lesion characterization. Additionally, the lesion location could be a relevant attribute. Lesions in the upper cervical spine might show slightly different DTI values than in the lower thoracic spine, because of the different anatomical constitution of the spinal cord. There are reports concerning diverging normal values between the cervical and thoracic spine [27]. Besides localization, the widely ranging age of all included patients (range 2–80 years, mean 45.4 (SD 18.3) years) can be a confounder too, whereas an age-dependency of DTI parameters is reported in the literature for measurements of the healthy spinal cord [30–33]. There are no reports of age-dependent alterations within tumorous areas so far, but an impact of patients’ age could not be addressed by our data. In principle, larger age- and gender-matched studies would be preferable, but due to the rare pathology of SCT this would reduce the evaluable sample size considerably.

Another limitation of our study is due to the DTI application in clinical routine. For the conventional evaluation of all spinal cord lesions, the high-resolution 3D T2 SPACE was used. The anatomical resolution of Diffusion-weighted MR images is notoriously not as good as for T1- or T2-weighted sequences, whereas a precise discrimination of tissue alterations on Diffusion-weighted images is limited. This complicates the evaluation of the DTI parameters when setting the ROI, because of the small anatomical structures dealing with the spinal cord. In principle, the highest image resolution would be desirable for anatomical discrimination as well as for the reduction of partial volume effects. But in clinical routine, there has to be always the compromise between the acquisition time of the study imaging, that must be tolerable for the patient, and an adequate resolution to address the aimed question. The applied resolution was chosen similarly to the reports within the literature [14–16, 26]. Another complicating factor is, that there is no conformity concerning the most reproducible and reliable ROI size and setting procedure. We chose a ROI size of two voxels, which was smaller than the previously described in the literature in order to avoid measuring surrounding structures to increase precision. The ROI were set directly at the DTI maps to avoid anatomically distortions. Another imaging limitation of this evaluation is the change of the MRI protocol, which was due to scanner updates after the measurement of 30 patients.

At the moment, there is still no radiological technique that reliably separates the different intramedullary tumor entities. For the future, we probably need an integration of different imaging resources with conventional MRI, DTI, MR spectroscopy or new innovative sequences in combination with international studies or registries, to gain a better non-invasive differentiation of intramedullary tumors.

CONCLUSIONS

We conclude, that even though a distinct differentiation of ependymomas and other SCT was not possible due to objective DTI metrics, a separation of inflammatory lesions was feasible in our study cohort based on FA and ADC values. This may avoid unnecessary surgery in patients with unclear intramedullary tumor-suspected lesions. To achieve better tumor differentiation, higher case numbers are needed, requiring larger (inter-) national registry studies.

DATA AVAILABILITY

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

REFERENCES

1. Tihan T, Chi JH, McCormick PC, Ames CP, Parsa AT. Pathologic and epidemiologic findings of intramedullary spinal cord tumors. Neurosurg Clin N Am. 2006;17:7–11.
2. Samartdzis D, Gilles CC, Shh P, O’Toole JE, Fessler RG. Intramedullary spinal cord tumors: part I-epidemiology, pathophysiology, and diagnosis. Glob Spine J. 2015;5:425–35.
3. Nakamura M, Ishii K, Watatanabe K, Tsuji T, Takahashi H, Matsumoto M, et al. Surgical treatment of intramedullary spinal cord tumors: prognosis and complications. Spinal Cord. 2008;46:282–6.
4. Jaiswal M, Shyam Mittal R. Outcome of operative intervention in intramedullary spinal cord tumours. Rom Neurosurg. 2014;21:283–91.
5. Wolf M, Kloth JK, Hänsel S, Rehnitz C, Wiedenhöfer B, Weber M-A. Radiologische Diagnostik intraduraler Tumoren: Teil 2: Spezielle Diagnostik intraduraler Tumoren und tumörähnlicher Läsionen. Diagnostik spinaler Tumoren. Teil 2: Spezielle Diagnostik intraduraler Tumoren und tumörähnlicher Läsionen. J Neurol Neurosurg Psychiatry. 2012;81:608–17.
6. Van Goethem JVM, van den Hauwe L, Ozsaral O, De Schepper AMA, Parizel PM. Spinal tumors. Eur J Radiol. 2004;50:159–76.
7. Abul-Kasim K, Thurner MM, McKeever P, Sundgren PC. Intramedullary spinal tumors: current classification and MRI features. Neuroradiology. 2008;50:301–14.
8. Ottenhausen M, Ntoutias G, Bodhinaiake I, Ruppert F-H, Schreiber S, Förschler A, et al. Intradural spinal tumors in adults—update on management and outcome. Neurosurg Rev. 2019;42:371–86.
9. Wostrack M, Meyer B. Intradura lumbarum Tumoren: Epidemiologie. Diagnostik und Therapie Wirbels. 2020;04:84–90.
10. Arima H, Hasegawa T, Ogawa D, Yamato Y, Kobayashi S, Yusaeda T, et al. Feasibility of a novel diagnostic chart of intramedullary spinal cord tumors in magnetic resonance imaging. Spinal Cord. 2014;52:769–73.
11. Kim DH, Kim JH, Choi SH, Sohn C-H, Yun TJ, Kim CH, et al. Differentiation between intramedullary spinal ependymoma and astrocytoma: comparative MRI analysis. Clin Radiol. 2014;69:29–35.
12. Clark CA, Werring DJ. Diffusion tensor imaging in spinal cord: methods and applications—a review. NMR Biomed. 2002;15:78–86.
13. Ducrues D, Lepeintre J-F, Fillard P, Louireau C, Tadim L, Lasjaunias P, MR diffusion tensor imagery and fiber tracking in 5 spinal cord astrocytomas. AJNR Am J Neuroradiol. 2006;27:214–6.
14. Setzer M, Murtagh RD, Murtagh FR, Eleraky M, Jain S, Marquardt G, et al. Diffusion tensor imaging tractography in patients with intramedullary tumors: comparison with intraoperative findings and value for prediction of tumor resectability. J Neurosurg Spine. 2010;13:371–80.
15. Choudri AF, Whitehead MT, Klimo P, Montgomery BK, Ades-Aron B, Fieremans E. Denoising applications for diffusion tensor imaging tractography in patients with intramedullary tumors: part I-epidemiology, pathophysiology, and diagnosis. Glob Spine J. 2015;5:425–35.
16. Maj E, Szemplińska B, Szczesliowski W, Prokopienko M, Cieszanowski A, Marchel A, et al. Role of diffusion tensor imaging parameters in the characterization and differentiation of infiltrating and non-infiltrating spinal cord tumors: preliminary study. Clin Neuroradiol. 2020;30:739–47.
17. McCormick PC, Torres R, Post KD, Stein BM. Intramedullary ependymoma of the spinal cord. J Neurosurg. 1990;72:523–32.
18. Cohen-Adad J. High-resolution DWI in brain and spinal cord with syngo RESOLVE. SIEMENS MAGNETOM Flash. (02/2012):16–23.
19. Kellner E, Dhihal R, Kiselev VG, Reissner M. Gibbs-ringing artifact removal based on local subvoxel-shifts. Magn Reson Med. 2016;76:1574–81.
20. Versaart J, Novakov DS, Christensen D, Ades-Aron B, Sijbers J, Fieremans E. Denoising of diffusion MRI using random matrix theory. Neuroimage. 2016;142:394–406.
21. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.
22. Egger K, Hohenhaus M, Van Veltghoven V, Heil S, Urbach H. Spinal diffusion tensor tractography for differentiation of intramedullary tumor-suspected lesions. Eur J Radiol. 2016;85:2275–80.
23. Vargas MI, Delavalle J, Jlassi H, Rilliet B, Viaillon M, Becker CD, et al. Clinical applications of diffusion tensor tractography for differentiation of intramedullary tumor-suspected lesions. Eur J Radiol. 2016;85:2275–80.
24. Zhao M, Shi B, Chen T, Zhang Y, Geng T, Qiao L, et al. Axial MR diffusion tensor imaging and tractography in clinical diagnosed and pathology confirmed cervical spinal cord astrocytoma. J Neurol Sci. 2017;375:43–51.
25. Gass A, Rocca MA, Agosta F, Ciccurelli O, Chard D, Valisena P, et al. MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. Lancet Neurol. 2015;14:443–54.
26. Liu X, Tian W, Kolar B, Hu R, Huang Y, Huang J, et al. Advanced MR diffusion tensor imaging and perfusion weighted imaging of intramedullary tumors and tumor like lesions in the cervicomedullary junction region and the cervical spinal cord. J Neurooncol. 2014;115:559–66.
27. Brander A, Koskinen E, Luoto TM, Hakulinen U, Helminen M, Savitlhi S, et al. Diffusion tensor imaging of the cervical spinal cord in healthy adult population: normative values and measurement reproducibility at 3T. Acta Radiol. 2014;55:478–85.
28. Wang Y, Wang M, Liang H, Yu Q, Yan Z, Kong M. Imaging and clinical properties of inflammatory demyelinating pseudotumor in the spinal cord. Neural Regen Res. 2013;8:2484–94.
29. Lee M, Epstein FJ, Rezai AR, Zagzag D. Nonneoplastic intramedullary spinal cord lesions mimicking tumors. Neurosurgery. 1998;43:788–94.
30. Vedantam A, Jirjis MB, Schmit BD, Wang MC, Ulmer JL, Kurpad SN. Diffusion tensor imaging of the spinal cord. Neurosurgery. 2014;74:1–8.
31. Agosta F, Laganà M, Valsasina P, Sala S, Dall’Ocio L, Sormani MP, et al. Evidence for cervical cord tissue disorganisation with aging by diffusion tensor MRI. NeuroImage. 2007;36:728–35.
32. Mamata H, Jolesz FA, Maier SE. Apparent diffusion coefficient and fractional anisotropy in spinal cord: age and cervical spondylosis-related changes. J Magn Reson Imaging. 2005;22:38–43.
33. Vedantam A, Jirjis MB, Schmit BD, Wang MC, Ulmer JL, Kurpad SN. Characterization and limitations of diffusion tensor imaging metrics in the cervical spinal cord in neurologically intact subjects. J Magn Reson Imaging. 2013;38:861–7.

ACKNOWLEDGEMENTS
We specially thank Hansjörg Mast for the support for MRI acquisition and Diana Gruninger for data management.

AUTHOR CONTRIBUTIONS
MH was responsible for conceptualization, methodology, patient inclusion and investigation, data analysis and writing of the original draft. YM was responsible for data management, radiological evaluation, and reviewing/editing of the manuscript. JHK, CS, and UH contributed to the conceptualization, patient acquisition, interpretation of the data, and reviewing/editing of the manuscript. JB and KW were involved in interpretation of the acquired data and reviewing/editing of the manuscript. KE was responsible for conceptualization and investigation of the study, methodology and patient acquisition. MR supported the technical evaluation of MRI/DTI parameters. NK was responsible for radiological evaluation and supervision, data analysis, reviewing, and editing of the manuscript.

FUNDING
Open Access funding enabled and organized by Projekt DEAL.

COMPETING INTERESTS
The authors declare no competing interests.

ETHICAL APPROVAL
The trial was approved by the local ethics committee of the University of Freiburg, Germany (registration 145/14) and listed at the German Clinical Trials Register (DRKS00008994).

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41393-021-00741-2.

Correspondence and requests for materials should be addressed to Marc Hohenhaus.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.